

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A, 17.06B and 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries the “**Group**”) hereby announces that on July 11, 2023, the Company has resolved to grant share options (the “**Options**”) to 25 eligible participants (the “**Grantees**”), to subscribe for up to an aggregate of 8,883,977 ordinary shares of the Company of US\$0.000005 each (the “**Shares**”) in the capital of the Company pursuant to the share scheme (the “**Share Scheme**”) adopted by the Company on June 27, 2023, subject to the acceptance of the Grantees.

Details of the Options are as follows:

Date of Grant:	July 11, 2023 (the “ Date of Grant ”)
Number of Grantees:	25 Grantees (including 3 Directors and 22 employees)
Exercise price of the Options granted:	HK\$2.054 per Share, representing the highest of (i) the closing price of HK\$2.000 per Share as stated in the daily quotations sheet issued by The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) on the Date of Grant; (ii) the average closing price of HK\$2.054 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of US\$0.000005
Number of Options granted:	8,883,977 Options (each Option shall entitle the holder of the Option to subscribe for one Share)
Validity period of the Options:	Ten (10) years from the Date of Grant

Vesting period of the Options: Among the total Options:

- (i) 8,283,977 Options shall be vested in three (3) years, 1/3 of which shall be vested on each anniversary of the Date of Grant; and
- (ii) 600,000 Options shall be vested in five (5) years, 1/5 of which shall be vested on each anniversary of the Date of Grant.

Performance targets:

The vesting of the Options is not subject to any performance targets.

The purpose of the Share Scheme is to provide incentive to eligible participants in order to promote the development and success of the business of the Group. The Options to be granted will give the Grantees an opportunity to have a personal stake in the Company and will help motivate the Grantees in optimizing their performance and efficiency. The number of Options to be granted are based on the work performance and potential of the Grantees and no additional performance target is imposed before the Options are vested to the Grantees. In view of the above, the remuneration committee of the Company (the “**Remuneration Committee**”) considered the grant of Options aligned with the purpose of the Share Scheme.

Clawback mechanism:

The Options granted will be subject to the clawback mechanism as set out in the offer letter of the grant of Options as determined by the Board, in particular, the lapse of Options upon cessation of employment of the Grantee and the cancellation of Options at the discretion of the Board.

Financial assistance:

There is no arrangement for the Group to provide any financial assistance to the Grantees to facilitate the purchase of the Shares under the Share Scheme.

Among the Grantees, 3,226,424 Options were granted to the Directors, with details as follows:

Name	Position	Number of Options
Chen Guoming	Executive Director	1,209,992
Zhao Liang	Executive Director	1,624,933
Yan Luying	Executive Director	391,499

In accordance with the Rule 17.04(1) of the Listing Rules, the independent non-executive Directors have approved the grant of the above Options to Directors.

The remaining 5,657,553 Options were granted to 22 employees of the Group.

None of the Options will be subject to approval by the Independent Shareholders, and save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them.

After the grant of the Options, the number of Shares available for future grant under the mandate of the Share Scheme is 232,222,354.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, July 12, 2023

As at the date of this announcement, the executive Directors of the Company are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors of the Company are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.